- Home
- BB vs LEGN Comparison
BB vs LEGN Comparison
Compare BB & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BB | LEGN |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.9B |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BB | LEGN |
|---|---|---|
| Price | $9.24 | $33.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $4.85 | ★ $61.33 |
| AVG Volume (30 Days) | ★ 36.8M | 2.8M |
| Earning Date | 04-09-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 169.23 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $549,100,000.00 | N/A |
| Revenue This Year | $12.21 | $42.68 |
| Revenue Next Year | $8.95 | $30.52 |
| P/E Ratio | $115.33 | ★ N/A |
| Revenue Growth | ★ 2.65 | N/A |
| 52 Week Low | $3.12 | $16.24 |
| 52 Week High | $10.93 | $45.30 |
Technical Indicators
Market Signals| Indicator | BB | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 66.87 | 60.90 |
| Support Level | $3.72 | $31.84 |
| Resistance Level | N/A | $34.54 |
| Average True Range (ATR) | 0.81 | 2.59 |
| MACD | 0.17 | 0.42 |
| Stochastic Oscillator | 63.67 | 63.44 |
Price Performance
Historical ComparisonAbout BB BlackBerry Limited
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises. The firm provides endpoint management and other secure communications software to enterprises, specializing in regulated industries like government and financial institutions. BlackBerry also has a sizable embedded software business primarily serving the automotive market, with some exposure to the industrial market.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.